1. Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005;162:441-449.
2. Emsley R, Chiliza B, Asmal L, Lehloenya K. The concepts of remission and recovery in schizophrenia. Curr Opin Psychiatry 2011;24:114-121.
3. Lehman AF. The well-being of chronic mental patients. Arch Gen Psychiatry 1983;40:369-373.
4. Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 2013;70:913-920.
5. Karow A, Moritz S, Lambert M, Schöttle D, Naber D. Remitted but still impaired? Symptomatic versus functional remission in patients with schizophrenia. Eur Psychiatry 2012;27:401-405.
6. Van Os J, Burns T, Cavallaro R, Leucht S, Peuskens J, Helldin L, et al. Standardized remission criteria in schizophrenia. Acta Psychiatr Scand 2006;113:91-95.
7. Boden R, Sundström J, Lindström E, Lindström L. Association between symptomatic remission and functional outcome in first-episode schizophrenia. Schizophr Res 2009;107:232-237.
8. Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 2004;161:473-479.
9. Bobes J, Ciudad A, Alvarez E, San L, Polavieja P, Gilaberte I. Recovery from schizophrenia: results from a 1-year follow-up observational study of patients in symptomatic remission. Schizophr Res 2009;115:58-66.
11. Hasegawa T, Hashimoto T, Kanahara N, Yamanaka H, Ishige M, Sato Y, et al. Identifying improvable employment-related factors in schizophrenia patients. Psychiatry Res 2018;266:199-205.
12. Bouwmans C, De Sonneville C, Mulder CL, Hakkaart-van Roijen L. Employment and the associated impact on quality of life in people diagnosed with schizophrenia. Neuropsychiatr Dis Treat 2015;11:2125-2142.
13. Salkever D, Slade EP, Karakus M. Gender-Specific Patterns Of Employment And Employment Transitions For Persons With Schizophrenia: Evidence From The Schizophrenia Care And Assessment Program (SCAP). 15th ed. In: Marcotte DE, editor. The Economics of Gender and Mental Illness West York Shire. Bingley: The Emerald Group Publishing Limited, 2004, p. 109-131.
14. Üçok A, Gorwood P, Karadayi G. Employment and its relationship with functionality and quality of life in patients with schizophrenia: EGOFORS Study. Eur Psychiatry 2012;27:422-425.
15. Kopelowicz A, Liberman RP, Ventura J, Zarate R, Mintz J. Neurocognitive correlates of recovery from schizophrenia. Psychol Med 2005;35:1165-1173.
18. Yüksel N, Soygür H, Tural Ü, Demet MM. Temel psikofarmakoloji. 1th edition. In: Yağcıoğlu EA, editor. Atipik Antipsikotikler. Ankara: Tuna Matbaacılık San, 2010, p. 813-814.
20. Boyer L, Richieri R, Guedj E, Faget-Agius C, Loundou A, Llorca PM, et al. Validation of a functional remission threshold for the Functional Remission of General Schizophrenia (FROGS) scale. Compr Psychiatry 2013;54:1016-1022.
23. Yildiz M, Erim R, Soygur H, Tural U, Kiras F. Development and validation of the Subjective Recovery Assessment Scale for patients with schizophrenia. Psychiatry Clin Psychopharmacol 2018;2:163-169.
24. Kostakoglu E, Batur S, Tiryaki A, Gogus A. Reliability and validity of the Turkish version of the Positive and Negative Syndrome Scale (PANSS). Turk Psikol Derg 1999;14:23-32.
25. Emiroğlu B, Karadayı G, Aydemir Ö, Üçok A. Validation of the Turkish version of the Functional Remission of General Schizophrenia (FROGS) scale. Arch Neuropsychiatry 2009;46(Suppl):S15-S24.
26. Soygür H, Aybaş M, Hınçal G, Aydemir Ç. Şizofreni hastaları için yaşam niteliği ölçeği: Güvenirlik ve yapısal geçerlik çalışması. Dusunen Adam J Psychiatry Neurol Sci 2000;13:204-210.
27. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976;33:766-771.
29. Yung AR, Phillips LJ, Yuen HP, Francey SM, McFarlane CA, Hallgren M, et al. Psychosis prediction: 12-month follow up of a high-risk (“prodromal”) group. Schizophr Res 2003;60:21-32.
30. Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra-high-risk group: psychopathology and clinical features. Schizophr Res 2004;67:131-142.
31. Türkiye İşsizlik oranları 2015. Available at:
www.tuik.com.tr. Accessed November 29; 2018.
32. Marwaha S, Johnson S, Bebbington P, Stafford M, Angermeyer MC, Brugha T, et al. Rates and correlates of employment in people with schizophrenia in the UK, France and Germany. Br J Psychiatry 2007;191:30-37.
33. Kaytaz BN, Abut FB, Yıldız M. Examınatıon of workıng lıfe In patıents wıth schızophrenıa and schızoaffectıve dısorder: a pılot study. J Health Sci Kocaeli Univ 2017;3:13-17.
35. Huber G, Gross G, Schüttler R. A long-term follow-up study of schizophrenia: psychiatric course of illness and prognosis. Acta Psychiatr Scand 1975;52:49-57.
36. Ulusal Eğitim İstatistikleri Veri Tabanı 2015. Available at:
www.tuik.com.tr. Accessed November 29; 2018.
37. Yıldız M, Yazıcı A, Böke O. Demographic and clinical characteristics in schizophrenia: a multi center cross-sectional case record study. Türk Psikiyatri Dergisi 2010;21:213-224.
40. Tihonen J, Mittendorfer-Rutz E, Tornianen M, Alexanderson K, Tanskane A. Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepine in patients with schizophrenia: an observational follow-up study. Am J Psychiatry 2016;173:600-606.
44. McGurk SR, Mueser KT. Cognitive functioning, symptoms, and work in sup- ported employment: a review and heuristic model. Schizophr Res 2004;70:147-173.
45. Mueser KT, Becker DR, Torrey WC, Xie H, Bond GR, Drake RE, et al. Work and non-vocational domains of functioning in persons with severe mental ill- ness: a longitudinal analysis. Nerv Ment Dis 1997;185:419-426.
49. Kukla M, Lysaker PH, Roe D. Strong subjective recovery as a protective factor against the effects of positive symptoms on quality of life outcomes in schizophrenia. Compr Psychiatry 2014;55:1363-1368.